After two doses , the B strain-specific antibody response to TIV was insufficient to meet the Center for Biologics Evaluation and Research ( CBER ) licensure criterion for seroprotection , whereas responses to the MF59-adjuvanted vaccine met the seroprotection criterion against all three strains .